Morningstar

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment bioAffinity Technologies, Inc.
University of Dayton

NIH funding UD engineers' mission to better detect pediatric lung nodules

UD News University of Dayton researchers are helping Cincinnati Children's Hospital Medical Center by developing artificial ...

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

Sales of bioAffinity's CyPath® Lung test for lung cancer reached a new high in Q3 2025, representing a 95% increase over the ...
Cure Today

Letters to My Lungs

Editor’s Note: This piece was submitted by a contributing writer and does not represent the views of CURE Media Group. September 2012, Hello, Dear lungs. I heard from my GP today that you showed up ...
Seeking Alpha

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment Ground-glass nodules appear in ...
The Globe and Mail

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released another compelling case study in ...